Avtozma 200 MG per 10 ML Injection

RxCUI
2705448
RxNorm name
Avtozma 200 MG per 10 ML Injection
Display name
Avtozma 200 MG per 10 ML Injection
Full name
Avtozma 200 MG per 10 ML Injection
Term type
SY
Status
DailyMed mapping
Updated
2026-06-04 23:38:59

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761420Avtozmatocilizumab-anoh351(k) InterchangeableRx2026-06-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set IDRxNorm stringTTYSPL versionLabelEffective
581c288f-8015-40ef-a4c3-683c96db193dAvtozma 200 MG per 10 ML InjectionSY4These highlights do not include all the information needed to use AVTOZMA safely and effectively. See full prescribing information for AVTOZMA. AVTOZMA ® (tocilizumab-anoh) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2025 AVTOZMA (tocilizumab-anoh) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful20260123
581c288f-8015-40ef-a4c3-683c96db193dAvtozma 20 MG/ML per 10 ML InjectionSY4These highlights do not include all the information needed to use AVTOZMA safely and effectively. See full prescribing information for AVTOZMA. AVTOZMA ® (tocilizumab-anoh) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2025 AVTOZMA (tocilizumab-anoh) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful20260123
581c288f-8015-40ef-a4c3-683c96db193dAvtozma 200 MG in 10 ML InjectionPSN4These highlights do not include all the information needed to use AVTOZMA safely and effectively. See full prescribing information for AVTOZMA. AVTOZMA ® (tocilizumab-anoh) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2025 AVTOZMA (tocilizumab-anoh) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful20260123
581c288f-8015-40ef-a4c3-683c96db193d10 ML tocilizumab-anoh 20 MG/ML Injection [Avtozma]SBD4These highlights do not include all the information needed to use AVTOZMA safely and effectively. See full prescribing information for AVTOZMA. AVTOZMA ® (tocilizumab-anoh) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2025 AVTOZMA (tocilizumab-anoh) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful20260123